Anti-diabetic effect of an alpha-glucan from fruit body of maitake (Grifola frondosa) on KK-Ay mice.
We have evaluated the anti-diabetic effect of a alpha-glucan (MT-alpha-glucan) from the fruit body of maitake mushrooms (Grifola frondosa) on KK-Ay mice (a kind of genetical type 2 diabetes animal model). The effects of MT-alpha-glucan (450 or 150 mg kg (-1)) on diabetic mice were investigated by observing the changes in body weight, the level of fasting plasma glucose, glycosylated serum protein (GSP), hepatic glycogen, serum insulin, triglycerides, cholesterol, free fatty acid, liver superoxide dismutase (SOD), glutathione peroxidase (GSHpx), reduced glutathione (GSH) and malondialdehyde (MDA). Moreover, the binding capacity of insulin receptors on liver crude plasma membranes was assayed and histopathological changes in the pancreas were observed. Treatment with MT-alpha-glucan significantly decreased the body weight, level of fasting plasma glucose, GSP, serum insulin, triglycerides, cholesterol, free fatty acid and MDA content in livers. Treatment with MT-alpha-glucan significantly increased the content of hepatic glycogen, GSH and the activity of SOD and GSHpx. Moreover, the insulin binding capacity to liver crude plasma membranes increased and histopathological changes in the pancreas were ameliorated in the treatment group. These data suggest that MT-alpha-glucan has an anti-diabetic effect on KK-Ay mice, which might be related to its effect on insulin receptors (i.e., increasing insulin sensitivity and ameliorating insulin resistance of peripheral target tissues).
Hong
Lei
L
School of Life Science and Technology, China Pharmaceutical University, Nanjing 210009, China.
Xun
Ma
M
Wutong
Wu
W
D000818:Animals; D001786:Blood Glucose / Q000187:drug effects; D001798:Blood Proteins / Q000187:drug effects; D001835:Body Weight / Q000187:drug effects; D002462:Cell Membrane / Q000187:drug effects / Q000378:metabolism; D002784:Cholesterol / Q000097:blood; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D004195:Disease Models, Animal; D005230:Fatty Acids, Nonesterified / Q000097:blood; D005260:Female; D005638:Fruit; D005936:Glucans / Q000302:isolation & purification / Q000494:pharmacology*; D005978:Glutathione / Q000187:drug effects; D005979:Glutathione Peroxidase / Q000187:drug effects; D006023:Glycoproteins / Q000187:drug effects; D048691:Grifola / Q000737:chemistry*; D007004:Hypoglycemic Agents / Q000302:isolation & purification / Q000494:pharmacology*; D007328:Insulin / Q000097:blood / Q000378:metabolism; D008099:Liver / Q000187:drug effects / Q000378:metabolism; D008112:Liver Glycogen / Q000032:analysis; D008315:Malondialdehyde / Q000378:metabolism; D051379:Mice; D010179:Pancreas / Q000187:drug effects / Q000473:pathology; D011972:Receptor, Insulin / Q000187:drug effects* / Q000378:metabolism; D013482:Superoxide Dismutase / Q000187:drug effects; D014280:Triglycerides / Q000097:blood; D000093422:Glycated Serum Proteins
D001786:Blood Glucose; D001798:Blood Proteins; D005230:Fatty Acids, Nonesterified; D005936:Glucans; D006023:Glycoproteins; D007004:Hypoglycemic Agents; D007328:Insulin; D008112:Liver Glycogen; D014280:Triglycerides; D008315:Malondialdehyde; D002784:Cholesterol; D005979:Glutathione Peroxidase; D013482:Superoxide Dismutase; D011972:Receptor, Insulin; D005978:Glutathione; D000093422:Glycated Serum Proteins